RAC Regulatory Affairs Certification Exam — Questions and Answers

Question 1: The systematic collection and analysis of real-world data from post-market surveillance serves as a primary input for the continuous update of which other key quality system process?

Risk Management (Correct answer)
Management Review
Supplier Controls
Design Controls

Correct answer: Risk Management

Post-market surveillance is a critical input to the risk management process, as described in ISO 14971. Data gathered from the market is used to review and update the risk management file, confirming that risk controls are effective and identifying any new hazards. This creates a continuous feedback loop, ensuring the risk profile of the device remains accurate throughout its lifecycle.

Question 2: A sponsor submits a Type II variation to the EMA. What does this typically involve?

An extension of the marketing authorization to a new indication
A minor administrative change to the dossier
A major change that may significantly affect the benefit-risk profile (Correct answer)
A change of Marketing Authorization Holder name only

Correct answer: A major change that may significantly affect the benefit-risk profile

A Type II variation involves a major change to a Marketing Authorization that may have a significant impact on the quality, safety, or efficacy of the product.

Question 3: When preparing for a Type A FDA meeting, which of the following is true regarding the meeting timeline?

FDA targets scheduling within 90 days
FDA must respond within 15 business days with written answers only
FDA targets scheduling within 30 days due to the urgent nature of Type A meetings (Correct answer)
Type A meetings are informal and have no scheduled timeline

Correct answer: FDA targets scheduling within 30 days due to the urgent nature of Type A meetings

Type A meetings are reserved for critical situations (e.g., clinical holds, dispute resolutions) and FDA targets scheduling within 30 days of receiving the meeting request.

Question 4: Under 21 CFR 807.87, which element is specifically required in the 510(k) submission to describe performance testing?

Performance data and testing protocols that demonstrate substantial equivalence (Correct answer)
A summary of the clinical investigation
A full quality management system audit report
An Environmental Impact Statement

Correct answer: Performance data and testing protocols that demonstrate substantial equivalence

21 CFR 807.87(e) requires performance data including test protocols and results that support the substantial equivalence determination.

Question 5: In the context of postmarket compliance, what does 'CAPA' stand for and what is its primary function?

Corrective Action and Preventive Action; identifying and eliminating the root causes of nonconformities (Correct answer)
Corrective and Preventive Audit; reviewing quality systems for compliance
Clinical and Postmarket Assessment; evaluating benefit-risk annually
Compliance Action and Performance Assessment; benchmarking against industry standards

Correct answer: Corrective Action and Preventive Action; identifying and eliminating the root causes of nonconformities

CAPA (Corrective Action and Preventive Action) is a quality system process focused on identifying root causes of nonconformities and preventing their recurrence.

Question 6: Which metric is MOST useful for tracking the efficiency of a regulatory affairs team's submission planning process over time?

Number of agency meetings attended annually
Cycle time from dossier lock to submission date (Correct answer)
Number of regulatory staff headcount
Total pages submitted per application

Correct answer: Cycle time from dossier lock to submission date

Cycle time from dossier lock to submission measures the internal efficiency of the submission preparation process and can reveal process bottlenecks.

Question 7: A pharmaceutical manufacturer receives an FDA Form 483 with three inspectional observations at the close-out of a GMP inspection. What is the most critical immediate action for the company?

Begin remediation but refrain from communicating with the FDA until all actions are complete.
Wait for the official Establishment Inspection Report (EIR) before taking any action.
Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs). (Correct answer)
Immediately file a formal dispute with the agency's legal counsel.

Correct answer: Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs).

The FDA expects a formal written response to a Form 483 within 15 business days. A timely and thorough response that acknowledges the observations and details the company's CAPA plan is crucial. This demonstrates a commitment to compliance and can help prevent the escalation of regulatory action, such as the issuance of a Warning Letter.

Question 8: Under 21 CFR Part 820, traceability requirements for implantable devices must ensure that each device can be traced to:

Its distributor and end-user location only
The inspector who performed final acceptance
The raw material supplier's ISO certification
The specific patient implanted, where required (Correct answer)

Correct answer: The specific patient implanted, where required

§820.65 requires that implantable devices be traceable to the patient who received them, to support effective field corrections and recalls.

Question 9: A regulatory professional must communicate an unexpected trial failure to multiple stakeholders including R&D, finance, and commercial teams. Which communication strategy is MOST effective?

Issue a press release first to ensure all internal groups receive the same message
Send a single detailed technical report to all groups simultaneously
Share information only with R&D until a recovery plan is established
Tailor separate briefings to each audience's specific concerns and decision needs, keeping a consistent core message (Correct answer)

Correct answer: Tailor separate briefings to each audience's specific concerns and decision needs, keeping a consistent core message

Tailoring messages to each audience's perspective while maintaining a consistent factual core ensures each stakeholder group can process the information and make appropriate decisions.

Question 10: Which ICH E6(R2) addendum requirement was specifically added to strengthen sponsor oversight of clinical trial quality?

Real-time electronic CRF submission to FDA
Mandatory site audits every 6 months
Increased IRB meeting frequency
Risk-based monitoring (RBM) and Quality Management Systems (QMS) (Correct answer)

Correct answer: Risk-based monitoring (RBM) and Quality Management Systems (QMS)

ICH E6(R2) introduced requirements for risk-based monitoring and a quality management system approach to identify and address critical data and process risks.

Question 11: Which term describes the process by which FDA orders a manufacturer to conduct post-market surveillance under Section 522 of the FD&C Act?

522 Order (Correct answer)
Warning letter
PMA supplement requirement
Consent decree

Correct answer: 522 Order

FDA issues a 522 Order (referencing Section 522 of the FD&C Act, codified at 21 CFR Part 822) to require post-market surveillance for certain Class II and III devices.

Question 12: Which FDA phase typically involves the LARGEST number of human subjects to establish efficacy and monitor adverse reactions in a general population?

Phase IV
Phase I
Phase II
Phase III (Correct answer)

Correct answer: Phase III

Phase III trials are large-scale studies (typically hundreds to thousands of subjects) designed to confirm efficacy and detect adverse reactions at a population level.

Question 13: Which of the following best describes the concept of 'mutual recognition' in the EU regulatory system?

All EU countries must accept EMA-approved products without review
A reciprocal agreement between the EU and US to share safety data
A process by which CHMP reviews all national authorizations
A procedure where one member state's marketing authorization is recognized and extended to other member states (Correct answer)

Correct answer: A procedure where one member state's marketing authorization is recognized and extended to other member states

The Mutual Recognition Procedure (MRP) allows a marketing authorization granted by one EU Reference Member State to be recognized and extended to other Concerned Member States.

Question 14: When planning a regulatory strategy for an orphan drug in the US, which benefit is most strategically valuable?

Automatic approval without clinical trials
Exemption from all post-marketing surveillance requirements
Seven years of market exclusivity post-approval (Correct answer)
Guaranteed Fast Track and Priority Review simultaneously

Correct answer: Seven years of market exclusivity post-approval

Orphan Drug Designation grants 7 years of US market exclusivity after approval, which is a major commercial and strategic incentive for developing treatments for rare diseases.

Question 15: Under 21 CFR Part 11, which control is REQUIRED for electronic records used in regulatory submissions?

Audit trails that capture who made changes, what was changed, and when (Correct answer)
Use of government-approved encryption only
Paper backup for all electronic entries
Physical storage at an FDA-registered facility

Correct answer: Audit trails that capture who made changes, what was changed, and when

21 CFR Part 11 mandates secure, computer-generated audit trails for electronic records to ensure data integrity and traceability for records submitted to or inspected by FDA.

Question 16: When should a regulatory strategy be formally reassessed during product development?

Only at NDA/BLA submission
At predefined decision points and when significant new data emerge (Correct answer)
Annually regardless of development milestones
Only when FDA issues a complete response letter

Correct answer: At predefined decision points and when significant new data emerge

Regulatory strategy should be reassessed at defined decision gates (e.g., end-of-Phase 2) and whenever significant new clinical, safety, or competitive data emerge.

Question 17: What is the maximum review period FDA targets for a Traditional 510(k) under MDUFA commitments?

60 calendar days
180 calendar days
30 calendar days
90 calendar days (Correct answer)

Correct answer: 90 calendar days

FDA's MDUFA performance goal for Traditional 510(k) review is 90 calendar days from receipt.

Question 18: A sponsor wants to conduct a single-dose PK study in six healthy volunteers using a microdose (≤100 mcg) to characterize absorption without triggering full IND requirements. Which IND category applies?

Exploratory IND (Correct answer)
Emergency IND
Treatment IND
Commercial IND

Correct answer: Exploratory IND

Exploratory INDs (Phase 0) permit very limited human exposure with microdoses primarily to obtain early pharmacokinetic or pharmacodynamic data.

Question 19: Which element is NOT required in an informed consent document under 21 CFR Part 50?

The approximate number of subjects in the study
Identification of the sponsor's legal counsel (Correct answer)
A statement that participation is voluntary
A description of foreseeable risks or discomforts

Correct answer: Identification of the sponsor's legal counsel

21 CFR 50.25 lists required elements of informed consent; identifying the sponsor's legal counsel is not among them.

Question 20: A company plans to launch its new pharmaceutical product in the United States and the European Union simultaneously. The most effective strategic regulatory planning would involve:

Preparing the US submission first and then adapting it for the EU several years later.
Submitting identical dossiers to both agencies without any country-specific modifications.
Focusing exclusively on the requirements of the larger market and hoping it satisfies the other.
Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset. (Correct answer)

Correct answer: Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset.

An effective global regulatory strategy involves integrating and harmonizing the requirements of different target regions from the beginning of product development. This proactive approach, often guided by ICH guidelines, helps streamline development, avoid redundant testing, and facilitate more efficient submissions. Simply adapting one region's dossier for another or submitting identical packages is often inefficient and can lead to significant delays or rejection, as specific local requirements would be missed.

Question 21: Under 21 CFR Part 820, which procedure must address the disposition of nonconforming product, including the use of concessions (use-as-is decisions)?

Nonconforming product procedure (Correct answer)
Purchasing controls procedure
Labeling controls procedure
CAPA procedure

Correct answer: Nonconforming product procedure

§820.90 requires manufacturers to establish procedures for nonconforming product, including how use-as-is or rework decisions are made and by whom.

Question 22: According to ICH E9(R1), what does the estimand framework primarily help clinical trial designers specify?

Sample size calculations
The precise clinical question a trial is intended to answer, including how intercurrent events are handled (Correct answer)
Randomization algorithms
Statistical significance thresholds

Correct answer: The precise clinical question a trial is intended to answer, including how intercurrent events are handled

ICH E9(R1) introduced the estimand framework to align the trial objective, design, and analysis by explicitly defining the treatment effect of interest and handling of intercurrent events.

Question 23: Which signal detection method involves reviewing spontaneous adverse event reports to identify unexpected patterns of device-related harm?

Disproportionality analysis (Correct answer)
Randomized controlled trial
Design FMEA
Process validation study

Correct answer: Disproportionality analysis

Disproportionality analysis is a statistical method used in pharmacovigilance and device surveillance to detect unexpected signals in spontaneous report databases.

Question 24: When a regulatory agency requests labeling negotiations that could significantly restrict the approved indication, which approach MOST effectively protects the sponsor's position?

Accept all agency-proposed label language to ensure approval speed
Withdraw and resubmit with a narrower indication from the outset
Present a counter-proposal supported by robust clinical data analyses and a clear benefit-risk argument (Correct answer)
Escalate the dispute directly to the agency's Office of the Commissioner

Correct answer: Present a counter-proposal supported by robust clinical data analyses and a clear benefit-risk argument

A data-supported counter-proposal demonstrates scientific rigor and provides the agency with evidence-based rationale, giving the strongest basis for negotiating a broader label.

Question 25: Under FDA's IND regulations, a sponsor must notify the agency and place a clinical hold if which situation arises?

A principal investigator changes institutions
A contract research organization is replaced mid-study
The study budget is revised significantly
An unexpected serious adverse event suggests an unreasonable risk to subjects (Correct answer)

Correct answer: An unexpected serious adverse event suggests an unreasonable risk to subjects

An unexpected serious adverse event (SUSAR) that suggests unreasonable risk to subjects triggers a clinical hold obligation under 21 CFR 312.

Question 26: Under 21 CFR Part 211, who bears ultimate responsibility for approving or rejecting drug products?

Plant operations director
Quality control unit (Correct answer)
Manufacturing department manager
Regulatory affairs director

Correct answer: Quality control unit

21 CFR 211.22 assigns responsibility for approving or rejecting all drug products to the quality control unit, which must be independent of production.

Question 27: A sponsor receives a Complete Response Letter (CRL) after FDA reviews an NDA. What does this action signify?

FDA has identified deficiencies preventing approval and outlines what must be addressed before reconsideration (Correct answer)
The application has been approved with labeling conditions
The application has been refused to file due to incompleteness at submission
A full advisory committee review is required before any action is taken

Correct answer: FDA has identified deficiencies preventing approval and outlines what must be addressed before reconsideration

A CRL is issued when FDA cannot approve an application in its current form, detailing specific deficiencies—clinical, manufacturing, or labeling—that the sponsor must resolve.

Question 28: A 510(k) submitter references a predicate device that was itself cleared through a 510(k). This is known as using a:

Series predicate
Split predicate
Primary predicate
Chained predicate (Correct answer)

Correct answer: Chained predicate

Chained predicates refer to using a device whose own clearance relied on a prior predicate, creating a chain of substantial equivalence going back to a pre-amendments device.

Question 29: A manufacturer uses contract manufacturers to produce subassemblies. Under 21 CFR Part 820, the primary manufacturer's obligation regarding these contractors is to:

Establish and maintain procedures to ensure they meet specified requirements (Correct answer)
Audit contractors annually and submit findings to FDA
Register each contractor as a medical device manufacturer
Hold contracts contingent on FDA pre-approval of the contractor facility

Correct answer: Establish and maintain procedures to ensure they meet specified requirements

§820.50 requires establishing procedures to ensure contractors meet specified requirements; the primary manufacturer retains full responsibility for quality system compliance.

Question 30: Which concept does ICH Q9 Quality Risk Management introduce as a foundation for risk-based decision-making?

Continual process verification
Design space and proven acceptable ranges
Risk assessment, risk control, and risk review (Correct answer)
Quality by design principles

Correct answer: Risk assessment, risk control, and risk review

ICH Q9 establishes risk assessment, risk control, and risk review as the core elements of a structured quality risk management process.

Question 31: Which of the following best describes the 505(b)(2) regulatory pathway?

An application that relies at least partly on published literature or prior FDA findings for safety/efficacy (Correct answer)
A pathway reserved for generic drug applications
An abbreviated pathway available only for orphan drugs
An application relying entirely on the applicant's own preclinical and clinical data

Correct answer: An application that relies at least partly on published literature or prior FDA findings for safety/efficacy

A 505(b)(2) NDA allows reliance on published literature or FDA's prior findings of safety and efficacy, reducing the data package required compared to a full 505(b)(1) NDA.

Question 32: Which FDA guidance describes the expectation that manufacturers maintain a vigilance system to detect, report, and correct problems with marketed devices?

FDA Guidance on De Novo Classification
FDA Guidance on Q-Submissions
FDA Guidance on Predetermined Change Control Plans
FDA Guidance on Medical Device Reporting for Manufacturers (Correct answer)

Correct answer: FDA Guidance on Medical Device Reporting for Manufacturers

FDA's MDR guidance for manufacturers outlines the vigilance system expectations, including what constitutes a reportable event and required timelines.

Question 33: What is the purpose of a 'Trend Report' under 21 CFR Part 803?

To summarize competitor device recalls
To notify FDA of increased rates of device-related events that exceed baseline thresholds (Correct answer)
To document changes in manufacturing processes
To report annual sales volumes to FDA

Correct answer: To notify FDA of increased rates of device-related events that exceed baseline thresholds

Trend reports notify FDA when MDR event rates exceed established baseline thresholds, signaling a potential safety signal.

Question 34: When a protocol deviation occurs at a site, the investigator's PRIMARY obligation is to:

Document and report the deviation per protocol and IRB requirements (Correct answer)
Amend the protocol retroactively
Terminate the affected subject immediately
Notify the FDA within 24 hours

Correct answer: Document and report the deviation per protocol and IRB requirements

Investigators must document protocol deviations and report them according to the protocol requirements and IRB policies.

Question 35: In regulatory strategic planning for a new molecular entity (NME), the end-of-Phase 2 (EOP2) meeting is critical primarily because:

It aligns the Phase 3 program design with FDA's requirements before committing major resources (Correct answer)
It finalizes the product label language
FDA approval is granted at this meeting if Phase 2 data are positive
It triggers automatic Priority Review designation

Correct answer: It aligns the Phase 3 program design with FDA's requirements before committing major resources

The EOP2 meeting allows sponsors to confirm that Phase 3 design, endpoints, and statistical approach meet FDA's requirements before investing in expensive pivotal trials.

Question 36: Under 21 CFR Part 211, which document must be prepared and followed for each batch of drug product?

Design history file
Device history record
Master batch record
Batch production record (Correct answer)

Correct answer: Batch production record

21 CFR 211.188 requires a batch production record prepared for each batch as an accurate reproduction of the master production record.

Question 37: When creating a strategic regulatory plan, the process of gathering and analyzing publicly available information on competitor products, regulatory agency decisions, and new guidance documents is known as:

Marketing research
Post-market surveillance
Regulatory intelligence (Correct answer)
Clinical trial monitoring

Correct answer: Regulatory intelligence

Regulatory intelligence is the process of gathering and analyzing publicly available regulatory, scientific, and legal information to inform a company's regulatory strategy. This activity helps a company understand the current regulatory landscape, anticipate changes, learn from competitors' experiences, and make more informed strategic decisions throughout the product lifecycle.

Question 38: Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?

Prioritizing the largest market first before others
Global regulatory harmonization strategy using ICH guidelines (Correct answer)
Delegating each region to separate uncoordinated teams
Sequential submissions to each region independently

Correct answer: Global regulatory harmonization strategy using ICH guidelines

A global harmonization strategy leveraging ICH guidelines enables concurrent submissions across regions by aligning data packages to shared standards.

Question 39: In the EU regulatory system, what is the 'centralised procedure' for medicinal product authorisation?

A mutual recognition process between two or more member states without EMA involvement
A fast-track process exclusively for orphan medicinal products
A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states (Correct answer)
A procedure where each EU member state independently evaluates and approves a product for its own territory

Correct answer: A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states

The centralised procedure results in a single EMA opinion and a European Commission decision granting a marketing authorisation valid across all EU and EEA countries.

Question 40: A key distinction between a regulatory STRATEGY and a regulatory PLAN is that a strategy:

focuses only on the post-market surveillance activities required for the product.
considers the entire product lifecycle and aligns regulatory activities with broader business objectives. (Correct answer)
is a simple checklist of submission documents and their due dates.
is only created after a product has been rejected by a regulatory agency.

Correct answer: considers the entire product lifecycle and aligns regulatory activities with broader business objectives.

A regulatory strategy is a comprehensive, high-level document that aligns regulatory activities with business goals over the entire product lifecycle. It is proactive and considers long-term objectives, such as target markets, competitive positioning, and lifecycle management. In contrast, a regulatory plan is more tactical, focusing on the specific tasks, timelines, and deliverables required to execute the strategy, such as a submission timeline.

Question 41: A dietary supplement label claims 'Supports healthy cholesterol levels already within normal range.' How is this claim classified under DSHEA?

Disease claim that requires an approved New Drug Application
Qualified health claim requiring FDA pre-authorization
Structure/function claim requiring a disclaimer that FDA has not evaluated the statement (Correct answer)
Nutrient content claim subject to 21 CFR Part 101 definitions

Correct answer: Structure/function claim requiring a disclaimer that FDA has not evaluated the statement

Qualifying a benefit claim by stating 'already within normal range' typically converts a potential disease claim to a permissible structure/function claim under DSHEA.

Question 42: A manufacturer develops a device intended to treat a condition that affects fewer than 8,000 people in the United States annually. Due to the small patient population, conducting large-scale clinical trials to prove effectiveness is not feasible. Which pathway offers a potential route to market for such a device?

Product Development Protocol (PDP)
Humanitarian Device Exemption (HDE) (Correct answer)
Abbreviated 510(k)
De Novo Classification Request

Correct answer: Humanitarian Device Exemption (HDE)

The Humanitarian Device Exemption (HDE) pathway is specifically designed for devices intended to treat or diagnose diseases or conditions affecting fewer than 8,000 individuals in the U.S. per year. This pathway exempts the device from the effectiveness requirements of a PMA, but the applicant must demonstrate that the probable benefit to health outweighs the risks and that there is no comparable device available.

Question 43: Under FDA's 21 CFR 312.23, which of the following is NOT a required section of an IND application?

Post-marketing surveillance plan (Correct answer)
Investigator's Brochure
Clinical protocols
Chemistry, Manufacturing, and Controls information

Correct answer: Post-marketing surveillance plan

A post-marketing surveillance plan is a post-approval requirement, not a component of an initial IND application.

Question 44: In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?

Whether the active ingredient has been approved in Europe
The manufacturing site's ISO certification status
The size of the patient population needing the drug
The brand drug's patent expiration date and market exclusivity status (Correct answer)

Correct answer: The brand drug's patent expiration date and market exclusivity status

Patent expiration and exclusivity periods (including 180-day exclusivity for first filers) are central to determining when and how a generic ANDA can be strategically filed.

Question 45: Under the EU regulatory framework, which procedure allows a centralized single application valid across all EU member states?

Centralized Procedure (CP) via EMA (Correct answer)
National Procedure in the reference member state
Mutual Recognition Procedure (MRP)
Decentralized Procedure (DCP)

Correct answer: Centralized Procedure (CP) via EMA

The Centralized Procedure through EMA results in a single marketing authorization valid across all EU/EEA member states, making it strategically advantageous for broad EU access.

Question 46: When developing a regulatory strategy for a combination product in the US, which FDA center typically takes lead jurisdiction?

Always CDRH regardless of drug component
The center chosen by the sponsor
The center with the most expertise in the primary mode of action (Correct answer)
Always CDER regardless of device component

Correct answer: The center with the most expertise in the primary mode of action

FDA assigns lead jurisdiction to the center whose regulation is most appropriate based on the primary mode of action of the combination product.

Question 47: Under 21 CFR Part 312, what is the maximum period an IND may remain on clinical hold before the FDA must provide written explanation?

120 days
90 days
30 days (Correct answer)
60 days

Correct answer: 30 days

FDA must notify the sponsor in writing of a clinical hold within 30 days of receiving the IND or amendment.

Question 48: Management review under 21 CFR Part 820 must be conducted with sufficient frequency to ensure that the quality system is:

Suitable and effective for its stated purposes (Correct answer)
Profitable and cost-efficient
Compliant with ISO 13485 requirements
Approved by a third-party notified body

Correct answer: Suitable and effective for its stated purposes

§820.20 requires management review to be conducted with sufficient frequency to ensure the quality system remains suitable and effective.

Question 49: What is the primary purpose of a Regulatory Liaison function within a pharmaceutical company?

To perform GMP inspections at contract manufacturers
To write clinical study protocols
To manage pharmacovigilance reporting obligations exclusively
To serve as the main point of contact managing communication and relationships with regulatory agencies (Correct answer)

Correct answer: To serve as the main point of contact managing communication and relationships with regulatory agencies

The Regulatory Liaison function manages ongoing communication, meeting requests, and relationship management with regulatory agencies to ensure productive and consistent interactions.

Question 50: A company must decide whether to pursue Breakthrough Therapy designation for a new oncology drug. Which criterion is MOST relevant to this designation?

The drug has been approved in at least one foreign market
Preliminary clinical evidence shows substantial improvement over existing therapies for a serious condition (Correct answer)
The drug targets an unmet need in a rare pediatric disease only
The manufacturing process uses a novel continuous manufacturing platform

Correct answer: Preliminary clinical evidence shows substantial improvement over existing therapies for a serious condition

Breakthrough Therapy designation requires preliminary clinical evidence showing substantial improvement over available therapies on a clinically significant endpoint for a serious condition.

Question 51: Which metric is MOST useful for quantifying the real-world safety signal in post-market surveillance data?

Complaint rate per units distributed (Correct answer)
Number of social media mentions
Gross revenue per product line
Total units manufactured per quarter

Correct answer: Complaint rate per units distributed

Expressing complaints as a rate per units distributed normalizes the data, allowing meaningful comparison across time periods and product versions.

Question 52: A manufacturer identifies a trend in field complaints suggesting a component is failing at an elevated rate. Under 21 CFR Part 820, the most appropriate initial response is to:

Notify the complaint source that the device is within specification
Initiate a CAPA investigation to determine root cause (Correct answer)
File an MDR with FDA immediately
Suspend all sales until the issue is resolved

Correct answer: Initiate a CAPA investigation to determine root cause

§820.100 requires that quality data sources, including complaints, be analyzed to identify existing and potential causes of nonconforming products, triggering a CAPA investigation.

Question 53: Which regulatory submission is required when a PMA-approved device manufacturer wants to make a significant change to the device's indication for use?

A 180-Day Supplement
A Panel-Track Supplement (Correct answer)
A Real-Time Supplement
A 30-day notice

Correct answer: A Panel-Track Supplement

Changes to indications for use that require new clinical data are submitted as Panel-Track Supplements, which may be reviewed by an FDA advisory panel.

Question 54: Which U.S. law established the FDA’s authority to oversee drug safety?

Kefauver-Harris Amendment
Drug Listing Act
Food, Drug, and Cosmetic Act (Correct answer)
Prescription Drug Marketing Act

Correct answer: Food, Drug, and Cosmetic Act

The Federal Food, Drug, and Cosmetic (FD&C) Act, passed in 1938, is the foundational law that granted the FDA its authority to regulate drugs, food, and cosmetics. It mandated that new drugs be proven safe before marketing and established requirements for labeling. While subsequent amendments like Kefauver-Harris added efficacy requirements, the FD&C Act initially established the FDA's core oversight of drug safety.

Question 55: Under 21 CFR 202.1, a prescription drug advertisement must include which element known as the 'brief summary'?

The drug's complete Phase III clinical trial results
Information relating to each side effect, warning, precaution, and contraindication in the approved labeling (Correct answer)
A comparative analysis with competing drugs in the same therapeutic class
A summary of the drug's mechanism of action and pharmacokinetics

Correct answer: Information relating to each side effect, warning, precaution, and contraindication in the approved labeling

The brief summary requirement under 21 CFR 202.1 mandates disclosure of all risk-related information from approved labeling in print drug advertisements.

Question 56: A pharmaceutical manufacturer receives a batch of active pharmaceutical ingredient that fails identity testing. What is the required disposition?

Reject and return or destroy the material (Correct answer)
Retest using a different method before rejecting
Use under a deviation if potency is acceptable
Place in quarantine and notify the supplier only

Correct answer: Reject and return or destroy the material

Under 21 CFR 211.84, components failing identity testing must be rejected and cannot be used in drug product manufacturing.

Question 57: A sponsor submits a 505(b)(2) NDA. What distinguishes this pathway from a standard 505(b)(1) application?

It requires no clinical data whatsoever
It bypasses the advisory committee review process
It relies at least in part on data not developed by the applicant, such as published literature or FDA's findings for a previously approved drug (Correct answer)
It is reserved exclusively for generic drug products

Correct answer: It relies at least in part on data not developed by the applicant, such as published literature or FDA's findings for a previously approved drug

A 505(b)(2) NDA allows applicants to rely on data they did not develop, including FDA's prior findings of safety and effectiveness for a referenced drug.

Question 58: Which section of a Common Technical Document (CTD) contains the clinical study reports?

Module 5 (Correct answer)
Module 3
Module 4
Module 2

Correct answer: Module 5

Module 5 of the CTD contains clinical study reports, including results of clinical pharmacology, efficacy, and safety studies.

Question 59: What is the concept of 'Quality by Design' (QbD) as applied to pharmaceutical product development under ICH Q8?

A post-market surveillance methodology for identifying product failures
A systematic, science-based approach that begins with predefined objectives and emphasizes understanding product and process knowledge to build quality in from the start (Correct answer)
A reactive approach that addresses quality defects after they occur during manufacturing
A regulatory shortcut that reduces the need for analytical method validation

Correct answer: A systematic, science-based approach that begins with predefined objectives and emphasizes understanding product and process knowledge to build quality in from the start

QbD is a proactive development philosophy where quality is designed into a product through deep scientific understanding of formulation and manufacturing variables that affect quality attributes.

Question 60: When developing a regulatory strategy, what is the primary purpose of pre-submission meetings and other formal interactions with health authorities?

To receive informal, non-binding feedback from competitors about the development plan.
To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process. (Correct answer)
To obtain a binding guarantee of product approval before submitting the formal application.
To negotiate lower user fees for the marketing application review.

Correct answer: To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process.

Formal interactions with health authorities, such as pre-submission meetings, are a critical component of regulatory strategy. Their main purpose is to allow sponsors to present their development plan and receive feedback, ask specific questions, and gain alignment on key issues before a formal marketing application is submitted. This proactive communication helps to identify and mitigate potential hurdles, clarify regulatory expectations, and ultimately reduce the risk of major delays or rejection during the review process.

Question 61: FDA's 'refuse to accept' (RTA) policy for 510(k)s is designed to:

Screen submissions upfront for administrative and threshold completeness before substantive review (Correct answer)
Authorize FDA to reject all submissions from manufacturers with past violations
Replace the substantial equivalence determination process
Permanently deny clearance for non-compliant devices

Correct answer: Screen submissions upfront for administrative and threshold completeness before substantive review

The RTA policy ensures that only substantially complete 510(k) submissions enter the formal review queue, improving overall efficiency.

Question 62: What is a key responsibility of regulatory affairs professionals?

Oversee daily operations
Manage hospital workflows
Ensure regulatory compliance (Correct answer)
Develop clinical trial protocols

Correct answer: Ensure regulatory compliance

Regulatory affairs professionals are responsible for ensuring that their company's products (drugs, devices, biologics) comply with all applicable laws, regulations, and guidelines set by regulatory bodies worldwide. This involves preparing and submitting regulatory documents, interacting with agencies, and advising internal teams on compliance strategies throughout the product lifecycle. Their role is critical for market access and product integrity.

Question 63: What is the purpose of the ICH guidelines?

International harmonization of drug regulations (Correct answer)
Standardize preclinical animal testing only
Local drug pricing regulation
Healthcare facility inspections

Correct answer: International harmonization of drug regulations

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and the pharmaceutical industry from various regions. Its purpose is to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for drug registration. This reduces duplication of testing and speeds up the availability of new medicines globally.

Question 64: In the context of Good Clinical Practice (GCP), which of the following is a primary responsibility of a clinical trial investigator?

Protecting the rights, safety, and well-being of trial subjects. (Correct answer)
Ensuring the commercial viability of the investigational product.
Verifying that all clinical trial participants are adequately compensated for their time.
Drafting the initial Investigational New Drug (IND) application for the sponsor.

Correct answer: Protecting the rights, safety, and well-being of trial subjects.

A fundamental principle of Good Clinical Practice (GCP), as outlined in ICH E6, is that the investigator's primary responsibility is to protect the rights, safety, and well-being of the human subjects participating in a clinical trial. While other responsibilities like ensuring data integrity and protocol adherence are crucial, they all serve this primary duty. Commercial viability (A) is the sponsor's concern. Drafting the IND (B) is a sponsor responsibility. Ensuring fair compensation (C) is an element managed through the IRB-approved informed consent process, but the overarching responsibility is subject protection.

Question 65: In the EU, what is the Centralised Procedure (CP) most appropriate for?

National products sold only in one member state
Products requiring only a Type IA variation
Generic medicines referencing older products
Products containing new active substances or designated orphan medicines (Correct answer)

Correct answer: Products containing new active substances or designated orphan medicines

The Centralised Procedure is mandatory for certain product categories including new active substances, biotechnology products, and orphan medicines, granting a single EU-wide marketing authorization.

Question 66: Under FDA's rolling review process, what is the primary strategic benefit for sponsors?

It is available for all drug applications regardless of designation
Rolling review eliminates the need for advisory committee meetings
Sponsors can submit completed sections of the NDA/BLA as data become available, potentially shortening overall review time (Correct answer)
FDA commits to a defined approval date before review begins

Correct answer: Sponsors can submit completed sections of the NDA/BLA as data become available, potentially shortening overall review time

Rolling review allows FDA to begin evaluating completed modules before the full dossier is submitted, compressing the review timeline for products with expedited designations.

Question 67: Under ISO 13485:2016, which clause specifically requires procedures for post-market surveillance activities including feedback and complaint handling?

Clause 4.1 — General Requirements
Clause 6.2 — Human Resources
Clause 8.2 — Monitoring and Measurement (Correct answer)
Clause 7.4 — Purchasing

Correct answer: Clause 8.2 — Monitoring and Measurement

ISO 13485:2016 Clause 8.2 covers monitoring and measurement, including customer feedback, complaint handling, and reporting to regulatory authorities.

Question 68: Which of the following records serves as the comprehensive 'recipe' or set of instructions for manufacturing a specific medical device, containing all procedures and specifications for a finished device?

Device History Record (DHR)
Device Master Record (DMR) (Correct answer)
Design History File (DHF)
Quality System Record (QSR)

Correct answer: Device Master Record (DMR)

The Device Master Record (DMR), as defined in 21 CFR 820, is a compilation of records containing the procedures and specifications for a finished device. It includes device specifications, production process specifications, quality assurance procedures, and packaging and labeling specifications. The DHF describes the design history, and the DHR provides evidence that a specific batch was made according to the DMR.

Question 69: A company wants to expand an approved drug's indication. Which US regulatory mechanism most strategically minimizes development burden if supportive data already exists?

Withdraw the original NDA and refile with expanded label
Submit a Prior Approval Supplement (PAS) or efficacy supplement to the existing NDA (Correct answer)
File a new NDA under a different trade name
Seek a separate Biologics License Application (BLA)

Correct answer: Submit a Prior Approval Supplement (PAS) or efficacy supplement to the existing NDA

An efficacy supplement (Prior Approval Supplement) to an existing NDA is the standard and most efficient pathway to expand approved indications using existing or new clinical data.

Question 70: What is the purpose of the EMA's PRIME (PRIority MEdicines) scheme?

To fast-track generics for essential medicines
To offer reduced fees for SME applicants only
To provide early and enhanced support for development of medicines that target unmet medical needs (Correct answer)
To streamline post-approval variations for approved biologics

Correct answer: To provide early and enhanced support for development of medicines that target unmet medical needs

PRIME provides enhanced early scientific support for medicines that offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.

Question 71: A company markets a product as 'clinically proven' in its advertising. According to FTC enforcement principles, what type of evidence is needed to substantiate this claim?

Internal company testing data reviewed by company scientists
At least one well-controlled clinical study demonstrating the claimed benefit (Correct answer)
Expert endorsement from a licensed physician affiliated with the company
Any published study, including observational research or case reports

Correct answer: At least one well-controlled clinical study demonstrating the claimed benefit

FTC interprets 'clinically proven' to imply at least one well-controlled clinical study, setting a higher substantiation bar than general efficacy claims.

Question 72: Under the Biosimilar pathway (351(k) of the PHS Act), what must an applicant demonstrate beyond showing no clinically meaningful differences from the reference product?

That the biosimilar is manufactured at the same facility as the reference product
That the reference product's patent has expired before filing
Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data (Correct answer)
That the biosimilar has the exact same amino acid sequence as the reference biological product

Correct answer: Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data

Biosimilar applicants must demonstrate biosimilarity through a totality-of-evidence approach; the higher standard of 'interchangeability' requires additional switching studies showing no diminished safety or efficacy.

Question 73: A regulatory affairs professional is assessing whether to use FDA's Breakthrough Therapy Designation (BTD). Which criterion is most critical?

The drug must treat a rare disease with fewer than 200,000 US patients
The drug must have orphan designation already granted
Phase 3 trials must already be completed
Preliminary clinical evidence shows substantial improvement over available therapy for serious conditions (Correct answer)

Correct answer: Preliminary clinical evidence shows substantial improvement over available therapy for serious conditions

BTD requires preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing therapies on a clinically significant endpoint for serious conditions.

Question 74: Under 21 CFR Part 803, what is the timeframe for submitting a Medical Device Report (MDR) for a death or serious injury caused by a device?

30 calendar days
10 calendar days (Correct answer)
5 calendar days
45 calendar days

Correct answer: 10 calendar days

Manufacturers must submit MDRs for deaths or serious injuries within 30 calendar days of becoming aware of the event.

Question 75: In the EU MDR (Regulation 2017/745), what is the minimum frequency for periodic safety update reports (PSURs) for Class IIb implantable devices?

Annually (Correct answer)
Only when a serious incident occurs
Every three years
Every five years

Correct answer: Annually

Under EU MDR Article 86, PSURs for Class IIb implantable devices must be updated at least annually.

Question 76: A manufacturer of a Class II medical device in the U.S. receives several customer complaints about a software glitch that causes the device to temporarily freeze. No patient injury has been reported, and the issue is resolved by rebooting the device. What is the most appropriate initial action for the manufacturer?

Investigate the complaints as part of the formal complaint handling process to determine the root cause and assess the risk. (Correct answer)
Note the events and summarize them in the next annual report to the FDA.
File a Medical Device Report (MDR) with the FDA within 5 working days.
Immediately initiate a Class I recall and notify all customers.

Correct answer: Investigate the complaints as part of the formal complaint handling process to determine the root cause and assess the risk.

According to the FDA's Quality System Regulation (21 CFR 820.198), manufacturers must have procedures for receiving, reviewing, and evaluating complaints. The required initial action is to investigate the issue to understand its root cause, frequency, and potential risk. This investigation will determine if further actions, such as a Medical Device Report (MDR) or a recall/correction, are necessary. Acting without a proper investigation would be premature.

Question 77: A regulatory affairs team is considering whether to use a Real-World Evidence (RWE) study to support a label expansion. The primary regulatory challenge with RWE is:

RWE can only be used for rare diseases
Demonstrating that the real-world data are fit for purpose and meet standards for reliability and relevance (Correct answer)
RWE studies are always more expensive than randomized controlled trials
FDA does not accept any RWE for regulatory decisions

Correct answer: Demonstrating that the real-world data are fit for purpose and meet standards for reliability and relevance

The primary challenge with RWE is demonstrating data fitness for purpose — the data must be of sufficient quality and relevance to support the specific regulatory decision.

Question 78: What does the term 'qualification' refer to in the context of GMP equipment validation?

Verifying that analytical methods are suitable for their intended use
Demonstrating that equipment is properly installed, operates correctly, and performs as intended (Correct answer)
Documenting that a process consistently produces a product meeting specifications
Confirming that suppliers meet quality standards

Correct answer: Demonstrating that equipment is properly installed, operates correctly, and performs as intended

Equipment qualification (IQ/OQ/PQ) demonstrates that equipment is installed correctly, operates as designed, and performs consistently within specified parameters.

Question 79: In Japan, which body is primarily responsible for the scientific evaluation of new drug applications submitted through the PMDA?

Japan Pharmaceutical Manufacturers Association (JPMA)
National Institute of Health Sciences (NIHS)
PMDA with final approval granted by MHLW (Correct answer)
Ministry of Health, Labour and Welfare (MHLW) only

Correct answer: PMDA with final approval granted by MHLW

PMDA conducts the scientific review and consultation, while MHLW grants the formal marketing approval (Shonin) based on PMDA's recommendation.

Question 80: In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:

To negotiate pricing and reimbursement terms
To obtain binding commitments on approval timelines
To gain EMA guidance on data requirements before a marketing authorization application (Correct answer)
To replace the CHMP review process for urgent products

Correct answer: To gain EMA guidance on data requirements before a marketing authorization application

EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.

Question 81: The concept of 'regulatory intelligence' in strategic planning involves:

Tracking adverse event reports in public databases
Reviewing only published FDA guidance documents quarterly
Monitoring competitor regulatory filings and agency guidance to inform strategy (Correct answer)
Conducting espionage on regulatory agency internal deliberations

Correct answer: Monitoring competitor regulatory filings and agency guidance to inform strategy

Regulatory intelligence involves systematically monitoring regulatory agency activities, competitor filings, guidance documents, and industry trends to inform and update regulatory strategy.

Question 82: What is the primary purpose of a Regulatory Affairs Strategic Plan (RASP)?

To document all adverse events during clinical trials
To replace the Quality Management System during development
To outline regulatory milestones, resources, and risk mitigation for product development (Correct answer)
To serve as the product labeling master document

Correct answer: To outline regulatory milestones, resources, and risk mitigation for product development

A RASP aligns regulatory activities with business objectives by defining milestones, resource needs, and contingency strategies throughout development.

Question 83: Under GCP, a Certificate of Analysis (CoA) for an investigational drug product must be retained by the:

IRB for the duration of the trial
Subject's primary care physician
Investigator at the site as part of the investigator site file (Correct answer)
FDA district office

Correct answer: Investigator at the site as part of the investigator site file

The CoA for investigational product must be maintained in the investigator site file (Trial Master File) per ICH E6 essential documents requirements.

Question 84: What is the purpose of a Special Protocol Assessment (SPA) agreement between a sponsor and FDA for a Phase III trial?

To grant automatic Breakthrough Therapy designation
To secure FDA agreement that the protocol design is acceptable to support a future NDA/BLA (Correct answer)
To allow expedited enrollment without informed consent
To waive IRB review requirements

Correct answer: To secure FDA agreement that the protocol design is acceptable to support a future NDA/BLA

An SPA provides sponsors with FDA's binding agreement that the protocol design, endpoints, and statistical analysis plan are acceptable for regulatory approval.

Question 85: What is required for an NDA/BLA applicant to use rolling review?

The product must be marketed in at least one foreign country
The product must have received a qualifying designation such as Fast Track, BTD, or Accelerated Approval (Correct answer)
The applicant must have a PDUFA agreement in place
The product must be a generic drug

Correct answer: The product must have received a qualifying designation such as Fast Track, BTD, or Accelerated Approval

Rolling review is available to products with Fast Track, Breakthrough Therapy, or similar qualifying designations, allowing FDA to review completed sections as they are submitted.

Question 86: Which phase of clinical trials focuses on therapeutic effectiveness?

Phase 2 (Correct answer)
Phase 3
Phase 1
Preclinical phase

Correct answer: Phase 2

Phase 2 clinical trials are designed to evaluate the drug's effectiveness for a specific indication in a larger group of patients, typically several hundred. This phase also continues to assess safety and determine the optimal dosage range. The primary focus is to gather preliminary data on whether the drug works as intended and to further characterize its side effects.

Question 87: When developing a global regulatory strategy for a pharmaceutical product, which of the following BEST describes a rolling submission approach?

Rolling over a previously approved submission to a new indication
Updating an existing submission on a scheduled annual basis
Submitting completed dossier sections to the agency as they become available rather than waiting for the full dossier (Correct answer)
Submitting separate applications simultaneously to all target markets

Correct answer: Submitting completed dossier sections to the agency as they become available rather than waiting for the full dossier

A rolling submission allows sponsors to submit completed sections of a marketing application progressively, often used to expedite review for promising therapies.

Question 88: Which of the following best describes a Complete Response Letter (CRL) from the FDA?

A letter approving a product for accelerated use
A letter granting full product approval
A letter notifying the applicant of deficiencies that must be addressed before approval (Correct answer)
A letter withdrawing a previously approved product

Correct answer: A letter notifying the applicant of deficiencies that must be addressed before approval

A CRL informs the sponsor that FDA cannot approve the application in its current form and lists the deficiencies that must be resolved.

Question 89: Under the Special 510(k) program, what is the primary basis for demonstrating substantial equivalence?

New clinical data
Design controls under 21 CFR Part 820 (Correct answer)
Published performance standards
An IDE study

Correct answer: Design controls under 21 CFR Part 820

The Special 510(k) relies on design controls to demonstrate that device modifications do not affect safety or effectiveness.

Question 90: A company is planning regulatory strategy for a biosimilar. Which study is uniquely required compared to a small-molecule generic?

Dissolution testing to demonstrate pharmaceutical equivalence
Only a bioequivalence study using single-dose PK in healthy volunteers
Comparative clinical immunogenicity and pharmacokinetic/pharmacodynamic studies versus the reference biologic (Correct answer)
A full Phase 3 efficacy trial in all reference product indications

Correct answer: Comparative clinical immunogenicity and pharmacokinetic/pharmacodynamic studies versus the reference biologic

Biosimilar development requires comparative PK/PD and immunogenicity studies versus the reference biologic because complex biological molecules cannot be characterized as identical through analytical testing alone.

Question 91: In a GMP environment, which out-of-specification (OOS) investigation step must occur before retesting?

CAPA implementation
Phase I laboratory investigation (Correct answer)
Batch disposition decision
Regulatory notification

Correct answer: Phase I laboratory investigation

FDA's 2006 OOS guidance requires a Phase I laboratory investigation to assess analyst error and instrument performance before any retesting.

Question 92: An Institutional Review Board (IRB) is reviewing a protocol for a Phase 3 clinical trial. According to ICH GCP, which of the following is the PRIMARY responsibility of the IRB?

Verifying the accuracy of the data collected at the clinical sites.
Confirming the sponsor has adequate financial resources to complete the study.
Protecting the rights, safety, and well-being of the human subjects participating in the trial. (Correct answer)
Ensuring the scientific validity and statistical robustness of the trial design.

Correct answer: Protecting the rights, safety, and well-being of the human subjects participating in the trial.

The fundamental purpose of an IRB is to protect the rights and welfare of human research subjects. While scientific design is reviewed to assess the risk/benefit ratio, the IRB's primary mandate is the ethical oversight and protection of participants, not statistical validation, data verification, or financial auditing.

Question 93: Which internal department is most often engaged during regulatory planning?

Logistics
Human Resources
Finance
Clinical and R&D teams (Correct answer)

Correct answer: Clinical and R&D teams

During regulatory planning, the regulatory affairs department works most closely with clinical and R&D teams because these departments generate the scientific data required for regulatory submissions. Regulatory professionals guide these teams on study design, data collection, and documentation to ensure compliance with regulatory standards. This collaboration is essential for developing a robust regulatory strategy and preparing comprehensive dossiers.

Question 94: Which FDA database is the PRIMARY source manufacturers must search when evaluating complaints for potential MDR reportability?

FDA FAERS (Adverse Event Reporting System)
FDA 510(k) Premarket Notification database
MAUDE (Manufacturer and User Facility Device Experience) (Correct answer)
DailyMed

Correct answer: MAUDE (Manufacturer and User Facility Device Experience)

MAUDE contains MDRs submitted by manufacturers, importers, and device facilities, making it the primary reference for evaluating complaint trends and MDR precedents.

Question 95: Which FDA designation provides 6 months of additional market exclusivity in exchange for conducting pediatric studies?

Orphan Drug Designation
Best Pharmaceuticals for Children Act (BPCA) written request fulfillment (Correct answer)
Accelerated Approval
Pediatric Priority Review Voucher

Correct answer: Best Pharmaceuticals for Children Act (BPCA) written request fulfillment

Fulfilling an FDA Written Request under BPCA grants sponsors 6 months of additional market exclusivity (pediatric exclusivity).

Question 96: A company plans to use a validated biomarker as a primary endpoint in a Phase II trial to support dose selection. What FDA pathway provides formal endorsement of this biomarker's use?

Fast Track designation
Biomarker Qualification Program (Correct answer)
Accelerated Approval pathway
Breakthrough Therapy designation

Correct answer: Biomarker Qualification Program

FDA's Biomarker Qualification Program formally evaluates and endorses a biomarker for a specific context of use in drug development.

Question 97: Under 21 CFR Part 820, which of the following best describes a 'critical device'?

A device that is life-sustaining, life-supporting, or substantially important to the prevention of health impairment (Correct answer)
A device with more than 10 reported adverse events
Any Class III device with PMA approval
A device marketed exclusively in ICU settings

Correct answer: A device that is life-sustaining, life-supporting, or substantially important to the prevention of health impairment

§820.3(e) defines a critical device as one that is intended to be used in humans to support or sustain life, or whose failure to perform when used as intended could result in serious injury.

Question 98: Under EU MDR, Serious Incidents must be reported to the relevant competent authority within what timeframe when the incident has caused or might have caused a serious public health threat?

Within 15 calendar days
Immediately, without undue delay and no later than 2 days after the manufacturer becomes aware (Correct answer)
Within 30 calendar days
Within 7 calendar days

Correct answer: Immediately, without undue delay and no later than 2 days after the manufacturer becomes aware

EU MDR Article 87 requires that serious public health threats be reported immediately and no later than 2 days after the manufacturer becomes aware.

Question 99: Which of the following BEST describes the purpose of a regulatory gap analysis?

Comparing current data packages against agency requirements to identify missing or insufficient evidence (Correct answer)
Auditing internal SOPs against GMP regulations
Identifying differences between a product's label and its promotional materials
Reviewing patent expirations relative to product lifecycle plans

Correct answer: Comparing current data packages against agency requirements to identify missing or insufficient evidence

A regulatory gap analysis systematically compares the existing data package against regulatory requirements to identify deficiencies that must be addressed before submission.

Question 100: In regulatory strategic planning, a 'critical path' analysis primarily helps identify:

Activities that directly impact the overall project timeline (Correct answer)
Which countries to enter first based on market size
The most cost-effective regulatory consultants
The optimal clinical study design

Correct answer: Activities that directly impact the overall project timeline

Critical path analysis identifies the sequence of dependent activities that determine the minimum time required to complete a project.

RAC Regulatory Affairs Certification Exam

The RAC exam, administered by RAPS, certifies regulatory affairs professionals in their knowledge of strategic planning, pre-marketing, post-marketing, and interfacing with regulatory authorities for drugs and devices.

100

Questions

120 min

Time Limit

75%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds